News

Precision Biologics announces publication of a new review article in Expert Review of Vaccines, September 1st, 2024.

Strattmont Group2024-09-09T11:34:10-04:00

Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...

Precision Biologics Awarded New Patent on NEO-201 for Treg Depletion

Strattmont Group2024-07-22T12:26:35-04:00

Precision Biologics awarded new US Patent on its lead monoclonal antibody NEO-201 for regulatory T-cell...

Precision Biologics to present at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting

Strattmont Group2024-05-31T11:23:21-04:00

Precision Biologics presents new data from ongoing clinical trial combining NEO-201 with pembrolizumab at the...

PRECISION BIOLOGICS TO PRESENT AT 7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 – May 1, 2024

Strattmont Group2024-04-26T16:30:11-04:00

7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 - May 1, 2024 Accelerating Robust, Durable &...

PRECISION BIOLOGICS TO PRESENT AT IMMUNO 2024, LONDON, UK, APRIL 25 – 26, 2024

Strattmont Group2024-04-26T16:25:51-04:00

IMMUNO 2024, LONDON, UK, APRIL 25 - 26, 2024 Day 1: Track 1: Discovery & Development:...

American Association for Cancer Research (AACR) 2024 Annual Meeting, April 8, 2024, San Diego, CA, San Diego Convention Center

Strattmont Group2024-04-05T19:29:33-04:00

Precision Biologics will present recent scientific data at the American Association for Cancer Research (AACR)...

Dr. Philip Arlen, CEO, to give two scientific talks in Tokyo, Japan, December 14th – 15th, 2023

Strattmont Group2023-12-12T14:53:11-05:00

Dr. Philip M. Arlen, President & CEO of Precision Biologics, Inc. will deliver a scientific...